Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Amortization of Deferred Charges: 2021-2022

Historic Amortization of Deferred Charges for SAB Biotherapeutics (SABS) over the last 2 years, with Sep 2022 value amounting to $24,717.

  • SAB Biotherapeutics' Amortization of Deferred Charges fell 40.09% to $24,717 in Q3 2022 from the same period last year, while for Sep 2022 it was $138,939, marking a year-over-year change of. This contributed to the annual value of $164,983 for FY2021, which is 0.03% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Amortization of Deferred Charges stood at $24,717 for Q3 2022, which was down 22.30% from $31,809 recorded in Q2 2022.
  • Over the past 5 years, SAB Biotherapeutics' Amortization of Deferred Charges peaked at $41,259 during Q1 2021, and registered a low of $24,717 during Q3 2022.
  • For the 2-year period, SAB Biotherapeutics' Amortization of Deferred Charges averaged around $37,531, with its median value being $41,207 (2022).
  • Data for SAB Biotherapeutics' Amortization of Deferred Charges shows a maximum YoY tumbled of 40.09% (in 2022) over the last 5 years.
  • Over the past 2 years, SAB Biotherapeutics' Amortization of Deferred Charges (Quarterly) stood at $41,206 in 2021, then crashed by 40.09% to $24,717 in 2022.
  • Its last three reported values are $24,717 in Q3 2022, $31,809 for Q2 2022, and $41,207 during Q1 2022.